GeoVax Labs (NASDAQ: GOVX) is stepping into 2026 talking like an inflection‑year story—and, unusually for biotech, it has the clinical, regulatory and manufacturing pieces to at least justify the wardrobe change. While capital remains tight, the company is pairing late‑stage Mpox vaccine…